The "skinny jab" is a colloquial term, popular in the UK and increasingly in the US, for injectable GLP-1 receptor agonist medications used for weight loss. It most commonly refers to semaglutide (brand names Ozempic and Wegovy), which produces average weight loss of 13 to 15% of body weight over 68 weeks in clinical trials. For comprehensive weight loss data, see our Semaglutide for Weight Loss: Complete Guide 2026 guide.
Key Takeaway
The skinny jab is semaglutide, a GLP-1 receptor agonist that reduces appetite by mimicking a gut hormone. STEP trial data shows 14.9% average body weight reduction over 68 weeks. It is a prescription medication with real side effects, not a shortcut, and weight regain after stopping is common without lifestyle changes.
Where Did the Term "Skinny Jab" Come From?
The phrase "skinny jab" originated in British tabloid media around 2022 and 2023, when Ozempic prescriptions surged in the UK for off-label weight loss use. The term stuck because it was catchy and simple. UK tabloids and celebrity magazines used it to describe the wave of injectable weight loss medications that were suddenly everywhere, from Hollywood red carpets to NHS waiting lists.
In the US, the equivalent slang is "skinny shot" or "skinny pen." Both terms refer to the same class of medications: GLP-1 receptor agonists, primarily semaglutide and tirzepatide. The casual naming has drawn criticism from medical professionals who argue it trivializes a prescription medication and encourages off-label use by people who may not meet clinical criteria [1].
Before GLP-1 agonists, the "skinny jab" label was sometimes applied to lipotropic B12 injections or HCG shots sold at weight loss clinics. Those earlier injections had little clinical evidence behind them. The current skinny jab, semaglutide, is different because it has extensive clinical trial data supporting its effectiveness.
How Does Semaglutide Work for Weight Loss?
Semaglutide is a synthetic version of GLP-1 (glucagon-like peptide-1), a hormone your gut releases after eating. GLP-1 does several things: it signals the pancreas to release insulin, slows stomach emptying (so you feel full longer), and acts on appetite centers in the brain to reduce hunger [2].
The natural GLP-1 hormone breaks down in minutes. Semaglutide is engineered to last about a week in the body, which is why it is given as a once-weekly injection. The extended half-life comes from structural modifications that allow the molecule to bind to albumin in the blood, protecting it from degradation.
The appetite suppression is the primary driver of weight loss. People on semaglutide report feeling satisfied with smaller meals, reduced food cravings, and less "food noise" (the constant mental preoccupation with eating). This is not willpower. It is a pharmacological change in how the brain processes hunger signals [2]. Many users report that food noise GLP-1 reduction is the most dramatic benefit.
How Semaglutide Works for a more detailed breakdown of the GLP-1 mechanism.
What Do the STEP Trials Show About Weight Loss?
The STEP (Semaglutide Treatment Effect in People with obesity) trials are the landmark studies behind semaglutide's FDA approval for weight management. They are the best data we have on what the skinny jab actually does.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →STEP 1 enrolled 1,961 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition. Participants received semaglutide 2.4 mg weekly or placebo, combined with lifestyle intervention. After 68 weeks, the semaglutide group lost an average of 14.9% of body weight, compared to 2.4% with placebo [3].
That translates to about 15.3 kg (33.7 lbs) of weight loss on average. About one-third of participants lost 20% or more of their body weight. These numbers are substantially better than any previous weight loss medication.
| Trial | Population | Duration | Avg. Weight Loss (semaglutide) | Avg. Weight Loss (placebo) |
|---|---|---|---|---|
| STEP 1 | Obesity/overweight without diabetes | 68 weeks | -14.9% | -2.4% |
| STEP 2 | Obesity/overweight with type 2 diabetes | 68 weeks | -9.6% | -3.4% |
| STEP 3 | Obesity + intensive behavioral therapy | 68 weeks | -16.0% | -5.7% |
| STEP 5 | Obesity/overweight, 2-year data | 104 weeks | -15.2% | -2.6% |
How Does the Skinny Jab Compare to Older Weight Loss Injections?
Before semaglutide, weight loss clinics commonly offered two types of injections: lipotropic B12 shots and HCG (human chorionic gonadotropin) injections. Neither has strong clinical evidence for weight loss [4].
Lipotropic injections combine B vitamins with amino acids like methionine, inositol, and choline. The theory is that they support fat metabolism and energy. Clinical trials have not demonstrated meaningful weight loss from these injections beyond placebo. They are still widely available at med spas and weight loss clinics.
HCG injections were popularized alongside a 500-calorie-per-day diet in the 1950s. The FDA has stated that HCG is not effective for weight loss and that any weight loss on HCG protocols is attributable to the severe caloric restriction, not the hormone. The FDA required HCG weight loss products to carry labeling stating they are not proven for weight loss [4].
Semaglutide is categorically different from both. It has FDA approval specifically for chronic weight management (as Wegovy), backed by phase 3 trials with thousands of participants and robust data. The comparison between old "skinny shots" and today's GLP-1 medications is not close.
What Are the Side Effects of Semaglutide?
Gastrointestinal side effects are the most common. In STEP 1, nausea occurred in 44% of semaglutide users (vs. 17% placebo), diarrhea in 30% (vs. 16%), vomiting in 24% (vs. 6%), and constipation in 24% (vs. 10%) [3].
Most GI side effects are worst during the dose escalation period (the first 16 to 20 weeks when the dose gradually increases). They tend to decrease as the body adjusts. About 7% of participants in STEP 1 discontinued semaglutide due to side effects.
Less common but more serious risks include pancreatitis, gallbladder disease, and a theoretical risk of medullary thyroid carcinoma (based on rodent studies, not confirmed in humans). Semaglutide carries a boxed warning about thyroid C-cell tumors based on animal data. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use semaglutide [2].
semaglutide side effects for a full breakdown of what to expect during treatment.
What Happens When You Stop the Skinny Jab?
Weight regain after stopping semaglutide is a real and well-documented problem. A 2026 meta-analysis found that people lost an average of 14.7 kg after about 9 months of treatment, but after stopping, they regained approximately 0.8 kg per month. Researchers estimated that people would return to their original weight about 1.5 years after starting treatment if they discontinued [5].
This is not unique to semaglutide. It reflects the biology of obesity: the hormonal and neurological changes that drive weight regain are persistent. Stopping the medication removes the appetite suppression, and the body's weight regulation system pushes back toward the higher set point.
This is why most obesity medicine specialists view GLP-1 medications as long-term or potentially lifelong therapy for many patients, similar to medications for blood pressure or cholesterol. The "jab it and done" framing implied by "skinny jab" is misleading in this respect.
How Much Does the Skinny Jab Cost?
Wegovy (semaglutide 2.4 mg for weight management) has a US list price of approximately $1,300 to $1,400 per month without insurance. Many commercial insurance plans now cover Wegovy with prior authorization, but coverage varies widely. Medicare does not currently cover anti-obesity medications, though legislation to change this has been proposed [6].
In the UK, Wegovy is available through the NHS via specialist Tier 3 weight management services for patients with BMI 35 or above with at least one weight-related health condition. NHS waiting times for these services range from 6 to 24 months depending on location. Private prescriptions in the UK run approximately 150 to 300 GBP per month [6].
Compounded semaglutide, available through telehealth providers like FormBlends, can be significantly less expensive than brand-name Wegovy. Compounded versions are prepared by licensed compounding pharmacies and prescribed by licensed providers, though they are not FDA-approved as finished products. The Is Compounded Semaglutide Still Legal in 2026? What Patients Need to Know market affects availability.
Who Is a Good Candidate for Semaglutide?
FDA-approved criteria for Wegovy require a BMI of 30 or higher (obesity), or BMI 27 or higher (overweight) with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. It is intended as an adjunct to reduced-calorie diet and increased physical activity [2].
Semaglutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or a history of pancreatitis. It should be used with caution in people with gastroparesis or severe GI conditions. Pregnant or breastfeeding women should not use semaglutide.
The best outcomes occur in people who combine the medication with dietary changes (especially adequate protein intake) and regular exercise, particularly resistance training to preserve lean muscle mass during weight loss. who qualifies for semaglutide
Frequently Asked Questions
Is the skinny jab the same as Ozempic?
The skinny jab usually refers to semaglutide, which is the active ingredient in both Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). Ozempic is often used off-label for weight loss at its diabetes dose, while Wegovy uses a higher dose (2.4 mg vs. 1 mg).
How much weight can you lose with the skinny jab?
Clinical trials show an average weight loss of about 15% of body weight over 68 weeks. For a 200-pound person, that is roughly 30 pounds. About one-third of participants lose 20% or more. Individual results vary based on starting weight, diet, exercise, and adherence.
Is the skinny jab safe?
Semaglutide has been studied in large clinical trials and has FDA approval. Common side effects include nausea, diarrhea, vomiting, and constipation, especially during dose escalation. Serious risks are rare but include pancreatitis and gallbladder problems. It should be prescribed and monitored by a licensed provider.
Do you regain weight after stopping the skinny jab?
Yes, weight regain is common after discontinuation. Studies show an average regain of about 0.8 kg per month after stopping. Most obesity specialists recommend long-term use combined with sustained lifestyle changes to maintain weight loss.
Is the skinny jab different from B12 weight loss shots?
Yes, completely. B12/lipotropic shots have no clinical trial evidence for meaningful weight loss. Semaglutide works through a specific hormonal mechanism (GLP-1 receptor activation) and has extensive phase 3 trial data showing 15% average weight loss. They are not comparable.
Can I get the skinny jab online?
Semaglutide is a prescription medication that requires evaluation by a licensed healthcare provider. Telehealth platforms like FormBlends connect patients with providers who can assess eligibility, prescribe the medication, and monitor treatment remotely. You cannot legally buy it without a prescription.
How long do you need to take the skinny jab?
There is no fixed duration. Many patients use it long-term to maintain weight loss. If discontinued, weight regain is likely without significant lifestyle modifications. Your provider can help determine the right approach based on your weight loss goals and overall health.
Medical References
- British Heart Foundation. Weight-loss injections explained. BHF.org.uk. Accessed April 2026.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Jastreboff AM, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2021;29(7):1145-1159. PMID: 34129012
- FDA. Questions and Answers on HCG Products for Weight Loss. U.S. Food and Drug Administration. 2020.
- Chemist-4-U. Weight loss injection statistics 2025-2026. Chemist-4-u.com. Accessed April 2026.
- Second Nature. The best weight-loss injections in 2026. Secondnature.io. Accessed April 2026.
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting any medication or protocol. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10